Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Frazier says companies should lobby for better education, healthcare and social justice, just like they lobby for business interests.

Merck CEO Ken Frazier Calls On Corporate America To Help Stabilize Society

AbbVie

Bristol-Myers

Johnson & Johnson

UnitedHealth Group

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

Wall Street Fund Managers Love These 5 Large Cap Health Care Stocks

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Issues 2019/2020 Corporate Responsibility Report

Merck Issues 2019/2020 Corporate Responsibility Report

Merck: You Should Own A Stake In This Pharma Company

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine in Adults with HIV-1 Infection

Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection

AstraZeneca

Invesco DWA SmallCap Momentum ETF

Inovio Pharmaceuticals

iShares Russell 2000 Growth ETF

iShares Morningstar Small-Cap Growth ETF

Moderna

Pfizer

Vanguard Small-Cap Growth

Vanguard Russell 2000 Growth 

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

Here's Why Small-Cap ETFs Are Hitting New Highs

Costco

Intel

ManpowerGroup

Netflix

NortonLifeLock

Panasonic Holdings Corp

Though it’s tempting to jump in on Wall Street’s hottest commodities, the under-the-radar nature of mature growth stocks to buy make them compelling in their own right. The post 7 Maturing Growth Stocks to Buy You Can Rely On appeared first on InvestorPlace.

7 Maturing Growth Stocks to Buy You Can Rely On

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Merck (MRK)

Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.

Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories

Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y.

Addressing the limitations of the current leading COVID-19 vaccines could be the key to long-term success.

This Late-to-the-Party Coronavirus Vaccine Maker Could Be the Biggest Winner Over the Long Run

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020

Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27

Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27

Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.

Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer

Lam Research

Microsoft

Target

Texas Instruments

Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.

Best Dividend Stocks for October 2020

MADISON, N.J.--(BUSINESS WIRE)---- $MRK #ForThemForUs--Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Bayer AG

Biogen

Bank of New York Mellon

British American Tobacco

Cerner

GlaxoSmithKline

Imperial Brands PLC

Altria

Philip Morris

Roche Holding AG

Wide-Moat Stocks On Sale - The October 2020 Heat Map

In the latest trading session, Merck (MRK) closed at $82.63, marking a -0.37% move from the previous day.

Merck (MRK) Stock Moves -0.37%: What You Should Know

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% Vs Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

Apple

Axovant Gene Therapies Ltd

American Express

JPMorgan Chase & Co

Coca-Cola

McDonald's

NIKE

Sutro Biopharma Inc

Walmart

Sio Gene Therapies

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM gene mutations, a subpopulation of homologous recombina

LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA Reduced Risk of Death by 31% for Men with BRCA1/2 or ATM-Mutated mCRPC Who Progressed Following Enzalutamide or Abiraterone in Ph 3 Trial

LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020

News for Merck Stock (MRK)